Responses With Asciminib Continue to Deepen Over Time in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs) in the Phase III ASCEMBL Study

被引：0

作者：

Mauro, Michael ^{[1
]}

Hochhaus, Andreas ^{[2
]}

Hughes, Timothy ^{[3
,4
]}

Rea, Delphine ^{[5
]}

Boquimpani, Carla ^{[6
]}

Minami, Yosuke ^{[7
]}

Apperley, Jane ^{[8
]}

Garcia-Gutierrez, Valentin ^{[9
]}

Kapoor, Shruti ^{[10
]}

Espurz, Noemi ^{[11
]}

Dhamal, Vishal ^{[12
]}

Cortes, Jorge ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Univ Klinikum Jena, Jena, Germany

[3] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[4] Univ Adelaide, Adelaide, SA, Australia

[5] Hop St Louis, Paris, France

[6] State Inst Hematol Arthur Siquiera Cavalcanti, HEMORIO, Rio De Janeiro, Brazil

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Ctr Haematol Imperial Coll London, London, England

[9] Hosp Univ Ramon & Cajal IRYCIS, Serv Hematol, Madrid, Spain

[10] Novartis Pharmaceut, E Hanover, NJ USA

[11] Novartis Pharma AG, Basel, Switzerland

[12] Novartis Healthcare Private Ltd, Hyderabad, India

[13] Georgia Canc Ctr, Augusta, GA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

CML; asciminib; TKI; ASCEMBL; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CML-398

引用

页码：S340 / S340

页数：1

共 50 条

[41] Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia
Ota, Shuichi
Matsukawa, Toshihiro
Yamamoto, Satoshi
Ito, Shinichi
Shindo, Motohiro
Sato, Kazuya
Kondo, Takeshi
Kohda, Kyuhei
Sakai, Hajime
Mori, Akio
Takahashi, Tohru
Ikeda, Hiroshi
Kuroda, Hiroyuki
Haseyama, Yoshihito
Yamamoto, Masaki
Sarashina, Takeo
Yoshida, Makoto
Kobayashi, Ryoji
Nishio, Mitsufumi
Ishihara, Toshimichi
Hirayama, Yasuo
Kakinoki, Yasutaka
Kobayashi, Hajime
Fukuhara, Takashi
Imamura, Masahiro
Kurosawa, Mitsutoshi
EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 95 - 105
[42] EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
Jabbour, Elias
Cortes, Jorge
Nazha, Aziz
O'Brien, Susan
Quintas-Cardama, Alfonso
Pierce, Sherry
Garcia-Manero, Guillermo
Kantarjian, Hagop
BLOOD, 2012, 119 (19) : 4524 - 4526
[43] Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia
Bostan, Hayri
Toptas, Tayfur
Tanrikulu, Funda Pepedil
Kut, Kevser
Arikan, Fatma
Yilmaz, Fergun
Atagunduz, Isik
Firatli-Tuglular, Tulin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (12) : 836 - 842
[44] The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
Jabbour, Elias
Kantarjian, Hagop
O'Brien, Susan
Shan, Jenny
Quintas-Cardama, Alfonso
Faderl, Stefan
Garcia-Manero, Guillermo
Ravandi, Farhad
Rios, Mary Beth
Cortes, Jorge
BLOOD, 2011, 118 (17) : 4541 - 4546
[45] Combination of Asciminib, a Novel and Specific BCR-ABL1 Inhibitor, Plus Imatinib in Previously Treated Chronic Myeloid Leukemia (CML) Patients: Phase 1 Study Results
Talpaz, Moshe
Cortes, Jorge
Lang, Fabian
Kim, Dong-Wook
Rea, Delphine
Mauro, Michael J.
Minami, Hironobu
Breccia, Massimo
DeAngelo, Daniel J.
Hochhaus, Andreas
Goh, Yeow Tee
Le Coutre, Philipp D.
Sondhi, Manu
Mishra, Kaushal
Hourcade-Potelleret, Florence
Vanasse, Gary
Aimone, Paola
Hughes, Timothy P.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S287 - S288
[46] Relationship Between High Body Mass Index (BMI) and Treatment Outcomes in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Dasatinib or Imatinib: Retrospective Analysis of the Phase 3 DASISION Trial
Breccia, Massimo
Cortes, Jorge E.
Shah, Neil P.
Saglio, Giuseppe
Jimenez-Velasco, Antonio
Le Coutre, Philipp
Brun, Alexander
DeGutis, Irene
Bathena, Sai
Sy, Oumar
Jabbour, Elias
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S230 - S230
[47] Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?
Jabbour, Elias
Kantarjian, Hagop M.
O'Brien, Susan
Shan, Jianqin
Quintas-Cardama, Alfonso
Garcia-Manero, Guillermo
Rios, Mary Beth
Cortes, Jorge E.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4260 - 4265
[48] Incidence of Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated with First-Line (1L) Tyrosine Kinase Inhibitors (TKI) in SIMPLICITY: An Observational Study
Goldberg, Stuart L.
Mauro, Michael
Cortes, Jorge
Keating, Scott J.
Bhandari, Hitesh
Chen, Clara
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S241 - S242
[49] First-in-Human Phase I Study of ELVN-001, an Oral, Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients With Chronic Myeloid Leukemia Who Failed Prior Tyrosine Kinase Inhibitors
Mauro, Michael
Lang, Fabian
Kim, Dong-Wook
Heinrich, Michael
Sasaki, Koji
Lyssikatos, Joe
Collins, Helen
Hochhaus, Andreas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S345 - S345
[50] Withdrawal Syndrome After Tyrosine Kinase Inhibitors Discontinuation in Patients with Chronic Myeloid Leukemia in Russian Prospective Study (RU-SKI)
Petrova, Anna
Chelysheva, Ekaterina
Shukhov, Oleg
Bykova, Anastasiya
Nemchenko, Irina
Gusarova, Galina
Tsyba, Nikolay
Ionova, Tatyana
Julhakyan, Hunan
Turkina, Anna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S291 - S292

← 1 2 3 4 5 →